Clinical Trial

Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD

Study acronym: TCMWINE
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of severe treatment-related adverse events of Yi-Qi-Qing-Jie formula (YQF) combined therapy compared with immunosuppression monotherapy in high-risk IgAN.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-01-25; most recent amendment 2024-09-24.
Status change: Recruiting → Active, Not Recruiting 2023-09-28
Status change: Not Yet Recruiting → Recruiting 2018-06-18
Trial Details
NCT Number NCT03418779
Lead Sponsor Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborators: China Academy of Chinese Medical Sciences
Conditions IgA Nephropathy at High Risk of Developing ESRD
Enrollment 60 participants
Start Date 2019-07-04
Primary Completion 2024-09-25 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-25